NTRA News and Press, Natera Inc. From 12/28/23

2023-12-28 14:52:16 ET More on NeoGenomics NeoGenomics, Inc. 2023 Q3 - Results - Earnings Call Presentation NeoGenomics, Inc (NEO) Q3 2023 Earnings Call Transcript NeoGenomics: Short-Term Upsides Possible, Long-Term Not Supported By Economic Value Natera wins...

2023-12-28 06:48:40 ET More on Natera Natera: Squeezing The Last Drop From NIPT Growth Engine Natera, Inc. (NTRA) Q3 2023 Earnings Call Transcript Natera, Inc. 2023 Q3 - Results - Earnings Call Presentation Merck to use Natera's database for oncology drug res...

2023-12-28 05:23:01 ET Summary CareDx specializes in solutions for transplant patients, but faces challenges, including legal setbacks and regulatory hurdles. The company won Medicare coverage for its HeartCare Multimodality Service and raised its revenue guidance for 2023. Ho...

Order enjoins NeoGenomics from making, using, selling or promoting its RaDaR molecular residual disease (MRD) assay in the United States with limited exceptions Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for...

2023-12-27 19:55:36 ET Summary Natera is a leading company in the field of molecular diagnostics, capitalizing on the growing potential and widespread application in modern healthcare. The company has a proven track record and established trust in the technology, offering investor...

2023-12-20 08:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Natera successfully achieves key objective for trial set to begin on Jan. 22nd Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion...

Includes new data from prospective clinical trials in HR+/HER2- breast cancer evaluating treatment on molecular recurrence (TOMR) and additional real-world data across all breast cancer subtypes Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced n...

2023-11-30 19:47:33 ET Summary Duquesne Family Office's 13F portfolio value decreased by 3% to $2.79B in Q3 2023. The largest holdings in the portfolio are Nvidia, Coupang, Microsoft, Eli Lilly, and Teck Resources, making up 53% of the portfolio. New stakes include Alphabet, V...

2023-11-14 10:28:23 ET More on Natera Natera, Inc. (NTRA) Q3 2023 Earnings Call Transcript Natera, Inc. 2023 Q3 - Results - Earnings Call Presentation Natera: Cash Burn Remains A Concern Canaccord sees solid Q3 earnings for medtech; likes Quanterix, Natera, G...